08:30-09:00 | Unveiling diabetes: how do diabetes and its treatments impact bone integrity? Kyoung Min Kim (Yonsei University, Korea) | |
09:00-09:30 | Beyond cholesterol: is dyslipidemia a hidden risk to bone health? Jinyoung Kim (The Catholic University of Korea, Korea) | |
09:30-10:00 | Skeletal vulnerability after bariatric surgery: mechanisms and preventive approaches Bukyung Kim (Kosin University, Korea) |
14:00-14:30 | Tailoring osteoporosis treatment: a task force update on goal-driven strategies Yumie Rhee (Yonsei University, Korea) | |
14:30-15:00 | Approaches to osteoporosis treatment failure: special considerations post-denosumab Yong Jun Choi (Ajou University, Korea) | |
15:00-15:30 | Low-dose and inhaled glucocorticoids: are they really safe for bone health? So Young Park (Kyung Hee University) |
11:20-11:50 | Dual sclerostin and DKK1 inhibition: promising BMD gains in first-in-human trial Matthew T. Drake (Mayo Clinic, USA) | |
11:50-12:20 | Emerging strategy for novel RANKL receptor-targeting osteoporosis therapeutics Wonbong Lim (Chosun University, Korea) | |
12:20-12:50 | Targeting tau: a low-affinity glucocorticoid receptor to treat glucocorticoid-induced osteoporosis Chuan-ju Liu (Yale University, USA) |